Abstract | BACKGROUND: DESIGN AND METHODS: Three cohorts of patients received escalating doses of monoclonal antibody 216 administered as an intravenous infusion. In the case of poor response to the first dose of monoclonal antibody 216 alone, defined as less than 75% reduction in peripheral blood blast count, a second dose of the antibody with vincristine was given between days 4 and 7. Responses were assessed weekly until day 35. Serum concentration of monoclonal antibody 216 was measured before and after infusion. Monoclonal antibody 216 targeting was determined with an anti-idiotypic antibody to monoclonal antibody 216 and preliminary efficacy was analyzed by changes in peripheral blood blasts. RESULTS: CONCLUSIONS:
|
Authors | Michaela Liedtke, Clare J Twist, Bruno C Medeiros, Jason R Gotlib, Caroline Berube, Marcia M Bieber, Neelima M Bhat, Nelson N Teng, Steven E Coutre |
Journal | Haematologica
(Haematologica)
Vol. 97
Issue 1
Pg. 30-7
(Jan 2012)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 21993685
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Neutralizing
- Antigen-Antibody Complex
- Antineoplastic Agents
- Vincristine
|
Topics |
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal
(immunology, pharmacokinetics, therapeutic use)
- Antibodies, Neutralizing
(blood, immunology)
- Antigen-Antibody Complex
(blood, immunology)
- Antineoplastic Agents
(pharmacokinetics, therapeutic use)
- Child
- Erythrocytes
(immunology)
- Female
- Humans
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Recurrence
- Treatment Outcome
- Vincristine
(therapeutic use)
- Young Adult
|